Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Reardon Andrew | CLO & Secretary | Sep 23 '24 | Option Exercise | 52.27 | 2,000 | 104,540 | 24,534 | Sep 25 08:54 PM | Reardon Andrew | CLO & Secretary | Sep 23 '24 | Sale | 99.60 | 2,000 | 199,201 | 22,534 | Sep 25 08:54 PM | Espinoza Octavio | Chief Financial Officer | Sep 20 '24 | Sale | 103.94 | 1,275 | 132,518 | 24,610 | Sep 24 07:41 PM | Korenberg Matthew E | President & COO | Sep 23 '24 | Option Exercise | 52.72 | 9,772 | 515,227 | 60,549 | Sep 24 07:41 PM | Korenberg Matthew E | President & COO | Sep 20 '24 | Option Exercise | 49.99 | 4,982 | 249,050 | 57,052 | Sep 24 07:41 PM | Korenberg Matthew E | President & COO | Sep 23 '24 | Sale | 101.22 | 9,772 | 989,121 | 50,777 | Sep 24 07:41 PM | Korenberg Matthew E | President & COO | Sep 20 '24 | Sale | 104.10 | 6,275 | 653,238 | 50,777 | Sep 24 07:41 PM | Reardon Andrew | Officer | Sep 23 '24 | Proposed Sale | 99.60 | 2,000 | 199,201 | | Sep 23 05:30 PM | Korenberg Matthew E | Officer | Sep 23 '24 | Proposed Sale | 101.50 | 14,437 | 1,465,403 | | Sep 23 05:27 PM | Korenberg Matthew E | Officer | Sep 20 '24 | Proposed Sale | 104.10 | 6,275 | 653,238 | | Sep 20 06:12 PM | Espinoza Octavio | Officer | Sep 20 '24 | Proposed Sale | 103.94 | 1,275 | 132,518 | | Sep 20 05:39 PM | Espinoza Octavio | Chief Financial Officer | Sep 17 '24 | Option Exercise | 79.63 | 1,486 | 118,328 | 25,885 | Sep 19 05:50 PM | Korenberg Matthew E | President & COO | Sep 16 '24 | Option Exercise | 58.49 | 5,774 | 337,696 | 54,008 | Sep 18 07:55 PM | Espinoza Octavio | Chief Financial Officer | Aug 28 '24 | Option Exercise | 66.52 | 753 | 50,086 | 24,399 | Aug 30 09:00 PM | Reardon Andrew | CLO & Secretary | Aug 28 '24 | Option Exercise | 52.27 | 1,500 | 78,405 | 24,034 | Aug 30 08:56 PM | Reardon Andrew | CLO & Secretary | Aug 28 '24 | Sale | 106.39 | 1,500 | 159,591 | 22,534 | Aug 30 08:56 PM | Reardon Andrew | Officer | Aug 28 '24 | Proposed Sale | 106.39 | 1,500 | 159,590 | | Aug 28 04:39 PM | Korenberg Matthew E | President & COO | Aug 26 '24 | Sale | 105.61 | 11,389 | 1,202,831 | 49,510 | Aug 26 08:15 PM | Korenberg Matthew E | President & COO | Aug 23 '24 | Sale | 104.80 | 6,312 | 661,479 | 60,899 | Aug 26 08:15 PM | Korenberg Matthew E | President & COO | Aug 22 '24 | Sale | 105.54 | 1,157 | 122,110 | 67,211 | Aug 26 08:15 PM | Korenberg Matthew E | Officer | Aug 22 '24 | Proposed Sale | 105.03 | 18,858 | 1,980,567 | | Aug 22 06:05 PM | Korenberg Matthew E | President & COO | Aug 09 '24 | Sale | 98.50 | 18,245 | 1,797,132 | 68,368 | Aug 13 05:21 PM | Davis Todd C | Chief Executive Officer | Aug 08 '24 | Buy | 97.39 | 2,500 | 243,480 | 123,010 | Aug 09 05:52 PM | Korenberg Matthew E | Officer | Aug 09 '24 | Proposed Sale | 98.50 | 18,245 | 1,797,132 | | Aug 09 05:16 PM | Gray Nancy Ryan | Director | May 09 '24 | Sale | 83.20 | 934 | 77,713 | 5,633 | May 17 08:00 PM | Espinoza Octavio | Chief Financial Officer | May 17 '24 | Option Exercise | 55.71 | 6,917 | 385,346 | 28,535 | May 17 07:59 PM | Espinoza Octavio | Chief Financial Officer | May 15 '24 | Sale | 86.01 | 5,873 | 505,148 | 23,882 | May 17 07:59 PM | Espinoza Octavio | Chief Financial Officer | May 17 '24 | Sale | 86.66 | 5,156 | 446,844 | 23,379 | May 17 07:59 PM | Espinoza Octavio | Chief Financial Officer | May 16 '24 | Sale | 86.00 | 2,264 | 194,712 | 21,618 | May 17 07:59 PM | Korenberg Matthew E | President & Chief Operating | May 14 '24 | Sale | 85.10 | 14,158 | 1,204,912 | 86,263 | May 15 07:34 PM | Korenberg Matthew E | President & Chief Operating | May 13 '24 | Sale | 84.54 | 3,440 | 290,828 | 100,421 | May 15 07:34 PM | Reardon Andrew | Chief Legal Officer & | May 09 '24 | Option Exercise | 52.27 | 10,000 | 522,700 | 32,205 | May 13 05:32 PM | Reardon Andrew | Chief Legal Officer & | May 09 '24 | Sale | 83.04 | 10,000 | 830,449 | 22,205 | May 13 05:32 PM | Aryeh Jason | Director | Apr 30 '24 | Option Exercise | 52.30 | 2,406 | 125,834 | 76,828 | May 02 06:07 PM | KOZARICH JOHN W | Director | Apr 24 '24 | Option Exercise | 39.35 | 2,893 | 113,840 | 42,523 | Apr 26 06:35 PM | Davis Todd C | Chief Executive Officer | Mar 25 '24 | Option Exercise | 57.39 | 16,015 | 919,147 | 120,160 | Mar 27 05:47 PM | Sabba Stephen L | Director | Mar 05 '24 | Option Exercise | 0.00 | 2,893 | 0 | 30,819 | Mar 07 01:27 PM | Sabba Stephen L | Director | Mar 05 '24 | Sale | 74.30 | 1,893 | 140,650 | 28,926 | Mar 07 01:27 PM | Aryeh Jason | Director | Mar 05 '24 | Option Exercise | 39.35 | 2,893 | 113,840 | 74,422 | Mar 06 05:28 PM | Espinoza Octavio | Chief Financial Officer | Feb 28 '24 | Option Exercise | 56.62 | 1,264 | 71,564 | 29,895 | Feb 29 06:50 PM | Espinoza Octavio | Chief Financial Officer | Feb 28 '24 | Sale | 88.46 | 140 | 12,384 | 29,755 | Feb 29 06:50 PM |
|